Literature DB >> 12720131

Predictive variables for malignant transformation in 452 patients with asymptomatic IgM monoclonal gammopathy.

Enrica Morra1, Clara Cesana, Catherine Klersy, Marzia Varettoni, Luigi Cavanna, Bianca Canesi, Elisabetta Tresoldi, Luciana Barbarano, Mario Lazzarino.   

Abstract

The natural history of asymptomatic IgM monoclonal gammopathies (MG) and variables predicting evolution to symptomatic lymphoproliferative disorders were investigated in 452 patients diagnosed from 1975 to 2001. Univariate and multivariate Cox models were used to identify possible predictors of disease progression. At a median follow-up of 49 months (range, 12 to 233), 41 cases (9.1%) evolved to symptomatic Waldenstrom's macroglobulinemia (n = 36), non-Hodgkin's lymphoma (n = 2), B-cell chronic lymphocytic leukemia (n = 1), IgM multiple myeloma (n = 1), and primary amyloidosis (n = 1); the median interval from diagnosis was 53 months (range, 12 to 154). The cumulative probabilities of transformation into a symptomatic lymphoproliferative disease at 5 and 10 years were 8% (95% confidence interval [CI], 6% to 12%) and 21% (95% CI, 16% to 29%), respectively. At univariate analysis, monoclonal component size and hemoglobin level as continuous parameters, lymphocytosis (>4 x 10(9)/L), bone marrow lymphoplasmacytoid infiltration (>10%), erythrocyte sedimentation rate (>40 mm/h), and detectable Bence Jones proteinuria were significantly related with evolution probability. At multivariate analysis, paraprotein level (P <.0001), hemoglobin level (P <.05), and lymphocytosis (P <.0001) independently predicted malignant evolution (P <.0001). In conclusion, patients with asymptomatic IgM-MG showing hematological features predictive of progression should be carefully monitored in view of an early treatment of the disease. Copyright 2003 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12720131     DOI: 10.1053/sonc.2003.50068

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  4 in total

1.  Occurrence of lymphoplasmacytic lymphoma 6 years after amelioration of primary cold agglutinin disease by rituximab therapy.

Authors:  Hiroaki Tanaka; Shinichiro Hashimoto; Yasumasa Sugita; Shio Sakai; Yusuke Takeda; Daijiro Abe; Toshiyuki Takagi; Chiaki Nakaseko
Journal:  Int J Hematol       Date:  2012-08-11       Impact factor: 2.490

Review 2.  Prevalence, clinical aspects, and natural history of IgM MGUS.

Authors:  Mary L McMaster; Ola Landgren
Journal:  Cytometry B Clin Cytom       Date:  2010       Impact factor: 3.058

3.  Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Aldo M Roccaro; Anne-Sophie Moreau; Sophie Dupire; Daniela Robu; Julie Gay; Evdoxia Hatjiharissi; Nicholas Burwik; Irene M Ghobrial
Journal:  Cancer Lett       Date:  2008-06-13       Impact factor: 8.679

4.  Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy.

Authors:  David F Moreno; Arturo Pereira; Natalia Tovar; María Teresa Cibeira; Laura Magnano; María Rozman; Mónica López-Guerra; Dolors Colomer; Beatriz Martín-Antonio; Raquel Jiménez-Segura; Ignacio Isola; Luis Gerardo Rodríguez-Lobato; Aina Oliver-Caldés; Mari Pau Mena; Laura Rosiñol; Joan Bladé; Carlos Fernández de Larrea
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.